CN112675295A - Blueberry powder compound solid preparation capable of preventing and improving osteoarthritis and preparation method and application thereof - Google Patents
Blueberry powder compound solid preparation capable of preventing and improving osteoarthritis and preparation method and application thereof Download PDFInfo
- Publication number
- CN112675295A CN112675295A CN202011451822.3A CN202011451822A CN112675295A CN 112675295 A CN112675295 A CN 112675295A CN 202011451822 A CN202011451822 A CN 202011451822A CN 112675295 A CN112675295 A CN 112675295A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- preventing
- blueberry
- compound solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 96
- 235000003095 Vaccinium corymbosum Nutrition 0.000 title claims abstract description 57
- 235000017537 Vaccinium myrtillus Nutrition 0.000 title claims abstract description 57
- 235000021014 blueberries Nutrition 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 37
- 239000007787 solid Substances 0.000 title claims abstract description 37
- 150000001875 compounds Chemical class 0.000 title claims abstract description 34
- 244000077233 Vaccinium uliginosum Species 0.000 title description 2
- 240000000851 Vaccinium corymbosum Species 0.000 claims abstract description 55
- 235000013305 food Nutrition 0.000 claims abstract description 23
- 235000009008 Eriobotrya japonica Nutrition 0.000 claims abstract description 22
- 102000000503 Collagen Type II Human genes 0.000 claims abstract description 19
- 108010041390 Collagen Type II Proteins 0.000 claims abstract description 19
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 17
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 17
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 241001092070 Eriobotrya Species 0.000 claims description 21
- 102000008186 Collagen Human genes 0.000 claims description 20
- 108010035532 Collagen Proteins 0.000 claims description 20
- 229920001436 collagen Polymers 0.000 claims description 20
- 240000000425 Chaenomeles speciosa Species 0.000 claims description 16
- 235000005078 Chaenomeles speciosa Nutrition 0.000 claims description 16
- 230000001954 sterilising effect Effects 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims description 5
- 239000011812 mixed powder Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 238000007908 dry granulation Methods 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 238000009928 pasteurization Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000005550 wet granulation Methods 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 235000020985 whole grains Nutrition 0.000 claims description 2
- 150000002978 peroxides Chemical class 0.000 abstract description 7
- 235000013373 food additive Nutrition 0.000 abstract description 6
- 239000002778 food additive Substances 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000001502 supplementing effect Effects 0.000 abstract description 5
- 208000002193 Pain Diseases 0.000 abstract description 4
- 210000003321 cartilage cell Anatomy 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 244000061508 Eriobotrya japonica Species 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 10
- 235000009508 confectionery Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 210000001188 articular cartilage Anatomy 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 5
- 210000001612 chondrocyte Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 235000010208 anthocyanin Nutrition 0.000 description 4
- 229930002877 anthocyanin Natural products 0.000 description 4
- 239000004410 anthocyanin Substances 0.000 description 4
- 150000004636 anthocyanins Chemical class 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 235000001465 calcium Nutrition 0.000 description 4
- 230000003467 diminishing effect Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- 229940059329 chondroitin sulfate Drugs 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- -1 polyphenol flavonoid glycoside compound Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000208421 Ericaceae Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 235000012511 Vaccinium Nutrition 0.000 description 2
- 241000736767 Vaccinium Species 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229940069978 calcium supplement Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 229940116298 l- malic acid Drugs 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 244000189799 Asimina triloba Species 0.000 description 1
- 235000006264 Asimina triloba Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 241001507936 Chaenomeles Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000005137 Joint instability Diseases 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 241000521581 Millettia Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000270273 Ptyas dhumnades Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 239000010681 turmeric oil Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a blueberry powder compound solid preparation capable of preventing and improving osteoarthritis and a preparation method and application thereof, the blueberry powder compound solid preparation capable of preventing and improving osteoarthritis comprises 10-90 parts by weight of blueberry powder, 10-150 parts by weight of non-denatured type II collagen, 10-100 parts by weight of sodium hyaluronate, 10-80 parts by weight of fructus chaenomelis speciosae powder and 10-80 parts by weight of loquat leaf powder, and the preparation method of the blueberry powder compound solid preparation capable of preventing and improving osteoarthritis comprises a) mixing, b) granulating, c) crushing and d) post-treatment, all components of the blueberry powder compound solid preparation prepared by the invention are common food, medicine and food homologous articles, new food raw materials, new food raw material termination articles, food additives and other articles allowed to eat by laws and regulations, can diminish inflammation, ease pain, enhance organism immunity, preventing peroxide from damaging cartilage cells and supplementing non-denatured type II collagen.
Description
[ technical field ] A method for producing a semiconductor device
The invention relates to the technical field of compound solid preparations, in particular to a blueberry powder compound solid preparation capable of preventing and improving osteoarthritis and a preparation method and application thereof.
[ background of the invention ]
Osteoarthritis is a chronic joint disease caused by multiple factors. Osteoarthritis is characterized by progressive loss of articular cartilage, subchondral bone sclerosis, osteophyte formation, and narrowing of the joint space, while damage to the soft tissues surrounding the joint is characterized by fibrosis and contracture of the joint capsule. Osteoarthritis can cause joint pain, stiffness, swelling, joint instability, and muscle weakness, thereby affecting the patient's motor function and reducing the patient's quality of life.
Currently, effective methods for treating arthritis mainly include drug therapy and surgical therapy. In the aspect of drug treatment, the drug mainly comprises analgesics, non-steroidal drugs and glucocorticoids. However, analgesics temporarily relieve the pain of the patient only for a short period of time, and do not inhibit or slow the progression of the condition; although non-steroidal drugs and glucocorticoids have therapeutic effects on arthritis, they have serious side effects, which make it difficult for patients to insist on taking them for a long time. In the aspect of surgical treatment, such as joint cleaning, osteotomy and artificial joint replacement surgery, the problems of large wound, susceptibility to infection, more postoperative complications and the like basically exist, the joint replacement surgery is expensive, and not all patients have economic bearing capacity.
Therefore, the common food, the medicinal and edible food, the new food raw material, the food additive and the like are adopted as raw and auxiliary materials to prepare safe and reliable common food or special food and the like which are suitable for different people and have the effects of preventing and improving the arthritis, and the like, so that the preparation method is very important, and especially has very important significance for improving the life quality of middle-aged and elderly people.
Chinese patent publication No. CN 110214947 a discloses a composition for preventing and treating osteoarthritis, which is prepared by mixing collagen, non-denatured collagen, chitosan oligosaccharide, turmeric and other auxiliary materials according to a certain proportion. The patent prevents and improves phenotype change of chondrocytes by supplementing collagen and chondroitin sulfate, but cannot prevent and improve damage of chondrocytes caused by peroxide, and does not consider that bacteriostasis and inflammation diminishing are required in the process of preventing and improving osteoarthritis. In addition, the patent promotes calcium absorption by supplementing chitosan oligosaccharide, however, calcium supplement and calcium absorption increase are difficult to prevent and improve osteoarthritis.
Chinese patent publication No. CN 110897159 a discloses a composition for preventing or treating joint diseases, which is prepared by mixing zaocys dhumnade, eucommia flower, pawpaw, coix seed, notoginseng, beautiful millettia root, ginseng, shark cartilage powder, chitosan oligosaccharide and bovine bone collagen peptide according to a certain proportion. The patent has the functions of strengthening tendons and activating collaterals, dispelling wind-damp and stopping arthralgia, tonifying liver and kidney and strengthening tendons and bones, but can not prevent and improve cartilage cell damage caused by peroxide, and does not consider that bacteria inhibition and inflammation diminishing are required in the process of preventing and improving osteoarthritis.
Chinese patent publication No. CN 110946874 a discloses a hyaluronic acid composition for relieving osteoarthritis, which is prepared by mixing hyaluronic acid, chondroitin sulfate, glucosamine, chitosan oligosaccharide, calcium, vitamin D, vitamin C and vitamin K2 in a certain proportion. The patent can prevent and improve the phenotype change of chondrocytes by reducing the loss of collagen II through the supplementation of hyaluronic acid, chondroitin sulfate, glucosamine, chitosan oligosaccharide and the like, but the main functions of the components are repeated, and the efficacies of the components are obviously reduced under the condition of no exogenous collagen II supplementation. In addition, the patent does not consider that bacteriostasis and inflammation diminishing are necessary in the process of preventing and improving osteoarthritis. Moreover, the calcium supplement and calcium absorption promotion components of this patent are of little effect in preventing and improving osteoarthritis.
[ summary of the invention ]
The invention aims to solve the problems in the prior art, provides a blueberry powder compound solid preparation capable of preventing and improving osteoarthritis, and a preparation method and application thereof, and the blueberry powder compound solid preparation can enhance the immunity of organisms, prevent peroxide from damaging cartilage cells, supplement non-denatured type II collagen and reduce the degradation of the type II collagen in human bodies, thereby preventing and improving the osteoarthritis and improving the life quality of middle-aged and elderly people.
In order to achieve the purpose, the invention is realized by the following technical scheme:
a blueberry powder compound solid preparation capable of preventing and improving osteoarthritis comprises, by weight, 10-90 parts of blueberry powder, 10-150 parts of non-denatured type II collagen, 10-100 parts of sodium hyaluronate, 10-80 parts of chaenomeles speciosa powder and 10-80 parts of loquat leaf powder.
Preferably, the blueberry and loquat leaf powder comprises, by weight, 20-90 parts of blueberry powder, 55-150 parts of non-denatured type II collagen, 35-100 parts of sodium hyaluronate, 20-80 parts of chaenomeles speciosa powder and 20-80 parts of loquat leaf powder.
Preferably, the blueberry powder and the non-denatured II type collagen are 40 parts by weight, 100 parts by weight, 90 parts by weight, 50 parts by weight and 50 parts by weight of the Chaenomeles speciosa powder and the loquat leaf powder.
Preferably, the blueberry and loquat leaf powder comprises, by weight, 20 parts of blueberry powder, 55 parts of non-denatured type II collagen, 35 parts of sodium hyaluronate, 20 parts of chaenomeles speciosa powder and 20 parts of loquat leaf powder.
Preferably, the blueberry powder, the non-denatured type II collagen 150, the sodium hyaluronate 100, the chaenomeles speciosa powder 80 and the loquat leaf powder 80 are contained in a weight ratio of 90 parts.
A preparation method of a blueberry powder compound solid preparation capable of preventing and improving osteoarthritis comprises the following steps:
a) mixing: weighing 10-90 parts of blueberry powder, 10-150 parts of non-denatured II type collagen, 10-100 parts of sodium hyaluronate, 10-80 parts of chaenomeles speciosa powder and 10-80 parts of loquat leaf powder in parts by weight, and putting into a mixing container to be uniformly mixed to obtain mixed powder;
b) and (3) granulation: carrying out wet granulation or dry granulation and size stabilization on the mixed powder obtained in the step a) to obtain mixed particles;
c) crushing: drying, crushing and sieving the mixed particles obtained in the step b) at low temperature to obtain screened powder;
d) and (3) post-treatment: removing metal foreign matters in the screened powder obtained in the step c), carrying out metal detection inspection after internal packaging, then sterilizing, and carrying out external packaging to obtain a finished product.
Preferably, in the step b), the number of the whole grains is 10 to 30.
Preferably, in the step c), the screening mesh number is 80-120 meshes, and the drying temperature is lower than 50 ℃.
Preferably, in the step d), the sterilization mode adopts ultra-high pressure sterilization, pasteurization or irradiation sterilization.
The application of the blueberry powder compound solid preparation capable of preventing and improving osteoarthritis is characterized in that the blueberry powder compound solid preparation capable of preventing and improving osteoarthritis is used as a main raw material or an auxiliary material and is added into common food, health-care food or medicines.
The general food, health food or medicine includes, but is not limited to, tablets, capsules, granules, oral liquid, hard candy, gel candy, solid beverage, liquid beverage, jelly, baked food, cake, etc.
Anthocyanin contained in blueberry powder is a polyphenol flavonoid glycoside compound, is a strong antioxidant and can remove peroxide in vivo. Because anthocyanin has an inhibiting effect on oxidative damage and death of astrocytes induced by H2O2, the survival rate of astrocytes treated by H2O2 can be obviously improved by supplementing blueberry anthocyanin, and chondrocyte apoptosis caused by peroxide is inhibited. In addition, anthocyanins can reverse the effect of H2O2 on autophagy, blocking the degeneration of articular cartilage and the development of osteoarthritis.
The non-denatured type II collagen is the most important collagen in the articular cartilage, accounts for about 90-95% of the total amount of the collagen, and is the most important component in the articular cartilage matrix. Type II collagen can form collagen fiber by oneself under normal conditions, forms big collagen fiber by tiny fibre gradually again, is the main part in the collagen fiber spatial grid structure, plays decisive action to this network structure's stability, directly plays supporting role to articular cartilage tissue.
The key step in the development of osteoarthritis is the destruction of the network of type ii collagen by external forces or the dissolution of chemicals such as collagenase. After being destroyed, the reticular structure can cause a series of changes in the aspects of biomechanics, biochemistry and the like of the articular cartilage, thereby causing and aggravating osteoarthritis. And the supplementation of the type II collagen can effectively avoid the compensatory repair and insufficient supplementation of the type II collagen, thereby offsetting the damage of the type II collagen and preventing the irreversible damage of the articular cartilage.
Sodium hyaluronate is a natural active substance, exists in joints in a free chain form, is the only amino glycan without sulfate groups, is mainly secreted by chondrocytes and synovial membrane B cells, is an important component of joint synovial fluid and cartilage matrixes, and can effectively reduce the decomposition and loss of type II collagen. But the content of sodium hyaluronate in human joints is lost with age, so that the supplementation of a certain amount of hyaluronic acid by an appropriate route is a good method for treating arthritis.
The chaenomeles speciosa contains a large amount of chaenomeles glycoside. The papain can be used for treating rheumatoid arthritis, relieving swelling and pain, positively influencing immunologic function and improving knee joint pathomorphological abnormality.
The loquat leaf is the leaf of loquat of Rosaceae, which contains various functional components, and can reduce primary and secondary foot swelling degree in different degrees, reduce multiple arthritis integral index, promote spleen lymphocyte proliferation and correct abnormal secretion of spleen lymphocyte and abdominal cavity macrophage, thereby playing a better role in preventing and improving arthritis.
The invention has the beneficial effects that:
1) all components of the blueberry powder compound solid preparation prepared by the invention are common food, medicinal and edible substances, new food raw materials, new food raw material censorship stopping substances, food additives and other substances which are allowed to be eaten by laws and regulations;
2) the blueberry powder compound solid preparation prepared by the invention can be used for diminishing inflammation, relieving pain, enhancing the immunity of an organism, preventing peroxide from damaging cartilage cells, simultaneously supplementing non-denatured type II collagen and reducing the degradation of the type II collagen in a human body, thereby preventing and improving osteoarthritis and improving the life quality of middle-aged and elderly people;
3) the blueberry powder compound solid preparation prepared by the invention has no toxic or side effect, is not suitable for infants and pregnant women, and is suitable for various people of different age groups, different physiques and different health conditions;
4) the blueberry powder compound solid preparation prepared by the invention can be used as a raw material or an auxiliary material, and can be prepared into various foods, health-care foods and medicines such as tablets, capsules, granules, oral liquid, hard candies, gel candies, solid beverages, liquid beverages, jellies, baked foods, cakes and the like.
The features and advantages of the present invention will be described in detail by embodiments in conjunction with the accompanying drawings.
[ description of the drawings ]
Fig. 1 is a flow chart of preparation and application of a blueberry powder compound solid preparation.
[ detailed description ] embodiments
The first embodiment is as follows:
firstly, 40 parts of blueberry powder, 100 parts of non-denatured type II collagen, 90 parts of sodium hyaluronate, 50 parts of chaenomeles speciosa powder and 50 parts of loquat leaf powder are weighed according to the weight proportion. Subsequently, the obtained mixed powder was subjected to wet granulation or dry granulation and size adjustment to obtain a mixed granule with a mesh size of 10 meshes. Subsequently, the obtained mixed granules were subjected to low-temperature drying at less than 50 ℃, pulverization and sieving, and the mesh number was 120 to obtain a sieved powder. And finally, removing metal foreign matters in the obtained screened powder by an iron remover, carrying out metal detection and inspection after carrying out inner packaging by adopting a food-grade or medicinal-grade PE bag, then carrying out sterilization by adopting an ultrahigh pressure sterilization mode, and carrying out outer packaging to obtain a finished product.
The blueberry powder is prepared by using wild or artificially-planted Ericaceae (Eri-caceae) and Vaccinium spp (Vaccinium spp) blueberry fruits as raw materials, performing pretreatment, extracting (optionally skipping the extraction step), filtering to remove residues, separating and concentrating the filtrate by column chromatography (optionally skipping the separation and concentration step by column chromatography), adding maltodextrin (optionally adding maltodextrin), drying and the like.
The finished product obtained in the steps can be used as a raw material, and can be prepared into common food, health food or medicines after adding a proper amount of auxiliary materials such as food additives, auxiliary agents and the like.
For example, 120 parts of energy-free sweetener and 110 parts of microcrystalline cellulose are added into a blueberry powder compound solid preparation finished product, uniformly mixed and directly filled to prepare hard capsules, granules, powder or solid beverages and the like; ② adding 120 parts of non-energy sweetener, 110 parts of microcrystalline cellulose and 50 parts of magnesium stearate in weight proportion into the finished blueberry powder compound solid preparation, mixing uniformly, and pressing into tablets, tabletting candies, hard candies and the like.
Example two:
weighing 20 parts of blueberry powder, 55 parts of non-denatured II type collagen, 35 parts of sodium hyaluronate, 20 parts of chaenomeles speciosa powder and 20 parts of loquat leaf powder.
The number of the screened meshes is 100 meshes, the sterilization mode is hot water pasteurization, and the other steps are the same as the first embodiment.
The finished product obtained in the steps can be used as a raw material, and can be prepared into common food, health food or medicines after adding a proper amount of auxiliary materials such as food additives, auxiliary agents and the like.
For example, 16.8 parts by weight of purified water is added into a hot water heating jacket stirring tank and heated to 50 ℃, 37 parts by weight of glycerin fatty acid ester, 100 parts by weight of sunflower seed oil and 68 parts by weight of turmeric oil are added into a blueberry powder compound solid preparation finished product, after the mixture is uniformly mixed, the mixture is added into the tank and is continuously stirred, 141.02 parts by weight of gelatin is added, after the gelatin is completely dissolved, 52.18 parts by weight of glycerin is added, and finally the mixture is uniformly stirred to be used as a colloid sandwich material, and a soft capsule, a sugar-free gel candy, a sugar-free jelly, a sugar-free sandwich gel candy, a jam, a baking sauce and the like are prepared on a machine.
Example three:
weighing 90 parts of blueberry powder, 150 parts of non-denatured II type collagen, 100 parts of sodium hyaluronate, 80 parts of chaenomeles speciosa powder and 80 parts of loquat leaf powder.
The number of the screening meshes is 80, and the other steps are the same as those of the first embodiment.
The finished product obtained in the steps can be used as a raw material, and can be prepared into common food, health food or medicines after adding a proper amount of auxiliary materials such as food additives, auxiliary agents and the like.
For example, 2000 parts of purified water is added into a hot water heating jacket stirring tank and heated to 38 ℃, 30 parts of chicory powder and 15 parts of potassium alginate are added into a blueberry powder compound solid preparation finished product, after the mixture is uniformly mixed, the mixture is added into the tank and continuously stirred, 120 parts of non-energy sweetener, 50 parts of citric acid and 50 parts of L-malic acid are weighed, the non-energy sweetener, the citric acid and the L-malic acid are dissolved by 500 parts of purified water and then added into the tank, the mixture is uniformly stirred, and finally the mixture is filled to prepare oral liquid, liquid beverage and the like.
The above embodiments are illustrative of the present invention, and are not intended to limit the present invention, and any simple modifications of the present invention are within the scope of the present invention.
Claims (10)
1. A blueberry powder compound solid preparation capable of preventing and improving osteoarthritis is characterized in that: the blueberry and loquat leaf powder feed comprises, by weight, 10-90 parts of blueberry powder, 10-150 parts of non-denatured II type collagen, 10-100 parts of sodium hyaluronate, 10-80 parts of chaenomeles speciosa powder and 10-80 parts of loquat leaf powder.
2. The compound solid preparation of blueberry powder capable of preventing and improving osteoarthritis as claimed in claim 1, wherein: the blueberry and loquat leaf powder feed comprises, by weight, 20-90 parts of blueberry powder, 55-150 parts of non-denatured II type collagen, 35-100 parts of sodium hyaluronate, 20-80 parts of chaenomeles speciosa powder and 20-80 parts of loquat leaf powder.
3. The compound solid preparation of blueberry powder capable of preventing and improving osteoarthritis as claimed in claim 2, wherein: comprises 40 parts of blueberry powder, 100 parts of non-denatured II type collagen, 90 parts of sodium hyaluronate, 50 parts of chaenomeles speciosa powder and 50 parts of loquat leaf powder.
4. The compound solid preparation of blueberry powder capable of preventing and improving osteoarthritis as claimed in claim 2, wherein: comprises 20 parts of blueberry powder, 55 parts of non-denatured II type collagen, 35 parts of sodium hyaluronate, 20 parts of chaenomeles speciosa powder and 20 parts of loquat leaf powder.
5. The compound solid preparation of blueberry powder capable of preventing and improving osteoarthritis as claimed in claim 2, wherein: comprises 90 parts by weight of blueberry powder, 150 parts by weight of non-denatured type II collagen, 100 parts by weight of sodium hyaluronate, 80 parts by weight of chaenomeles speciosa powder and 80 parts by weight of loquat leaf powder.
6. A preparation method of a blueberry powder compound solid preparation capable of preventing and improving osteoarthritis is characterized by comprising the following steps:
a) mixing: weighing 10-90 parts of blueberry powder, 10-150 parts of non-denatured II type collagen, 10-100 parts of sodium hyaluronate, 10-80 parts of chaenomeles speciosa powder and 10-80 parts of loquat leaf powder in parts by weight, and putting into a mixing container to be uniformly mixed to obtain mixed powder;
b) and (3) granulation: carrying out wet granulation or dry granulation and size stabilization on the mixed powder obtained in the step a) to obtain mixed particles;
c) crushing: drying, crushing and sieving the mixed particles obtained in the step b) at low temperature to obtain screened powder;
d) and (3) post-treatment: removing metal foreign matters in the screened powder obtained in the step c), carrying out metal detection inspection after internal packaging, then sterilizing, and carrying out external packaging to obtain a finished product.
7. The preparation method of the blueberry powder compound solid preparation capable of preventing and improving osteoarthritis as claimed in claim 6, wherein the preparation method comprises the following steps: in the step b), the number of the whole grains is 10-30 meshes.
8. The preparation method of the blueberry powder compound solid preparation capable of preventing and improving osteoarthritis as claimed in claim 6, wherein the preparation method comprises the following steps: in the step c), the screening mesh number is 80-120 meshes, and the drying temperature is lower than 50 ℃.
9. The preparation method of the blueberry powder compound solid preparation capable of preventing and improving osteoarthritis as claimed in claim 6, wherein the preparation method comprises the following steps: in the step d), the sterilization mode adopts ultrahigh pressure sterilization, pasteurization or irradiation sterilization.
10. The application of the blueberry powder compound solid preparation capable of preventing and improving osteoarthritis is characterized in that: the blueberry powder compound solid preparation capable of preventing and improving osteoarthritis as claimed in claim 1 is added into common food, health food or medicines as a main raw material or an auxiliary material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011451822.3A CN112675295A (en) | 2020-12-10 | 2020-12-10 | Blueberry powder compound solid preparation capable of preventing and improving osteoarthritis and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011451822.3A CN112675295A (en) | 2020-12-10 | 2020-12-10 | Blueberry powder compound solid preparation capable of preventing and improving osteoarthritis and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112675295A true CN112675295A (en) | 2021-04-20 |
Family
ID=75448868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011451822.3A Pending CN112675295A (en) | 2020-12-10 | 2020-12-10 | Blueberry powder compound solid preparation capable of preventing and improving osteoarthritis and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112675295A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114794489A (en) * | 2022-04-20 | 2022-07-29 | 河南磐康健康管理股份有限公司 | Composition for preventing and improving joint diseases and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181294A (en) * | 2007-06-22 | 2008-05-21 | 北京星昊医药股份有限公司 | Pharmaceutical composition for curing osteoarthritis |
| CN109106944A (en) * | 2018-10-10 | 2019-01-01 | 安徽盛美诺生物技术有限公司 | It is a kind of prevent and treat osteoarthritis composition and its application |
| CN109395030A (en) * | 2018-12-29 | 2019-03-01 | 江苏朸健生命科技发展有限公司 | The composition and preparation method and purposes of relief from osteoarthritis disease |
| CN111467481A (en) * | 2020-05-08 | 2020-07-31 | 江苏新中基生物科技有限公司 | Composition for improving and/or preventing osteoarthritis and application thereof |
-
2020
- 2020-12-10 CN CN202011451822.3A patent/CN112675295A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181294A (en) * | 2007-06-22 | 2008-05-21 | 北京星昊医药股份有限公司 | Pharmaceutical composition for curing osteoarthritis |
| CN109106944A (en) * | 2018-10-10 | 2019-01-01 | 安徽盛美诺生物技术有限公司 | It is a kind of prevent and treat osteoarthritis composition and its application |
| CN109395030A (en) * | 2018-12-29 | 2019-03-01 | 江苏朸健生命科技发展有限公司 | The composition and preparation method and purposes of relief from osteoarthritis disease |
| CN111467481A (en) * | 2020-05-08 | 2020-07-31 | 江苏新中基生物科技有限公司 | Composition for improving and/or preventing osteoarthritis and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 何英姿;: "枇杷叶有效成分提取及药理作用研究进展", 广西工学院学报 * |
| 王云亮等: "药用木瓜的综合开发利用", 《河北农业科学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114794489A (en) * | 2022-04-20 | 2022-07-29 | 河南磐康健康管理股份有限公司 | Composition for preventing and improving joint diseases and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102287247B1 (en) | The composition of joint nutritional supplement for companion animals | |
| CN109106944B (en) | Composition for preventing and treating osteoarthritis and application thereof | |
| KR101738912B1 (en) | Composition For Anti-obesity And Diet | |
| CN102077934B (en) | Special dietary marine food for patients with high blood pressure | |
| JP5588351B2 (en) | Formulation containing rosehip extract | |
| CN103652862B (en) | Health food with functions of detoxifying and losing weight and preparation method thereof | |
| WO2011047518A1 (en) | Enteral nutrition comprising marine bioactive polysaccharide, preparation method and use thereof | |
| DE202007011252U1 (en) | Amino sugar-containing product | |
| CN106605914A (en) | Composition capable of lubricating the intestines, relaxing the bowels, expelling toxin and expelling lead, as well as preparation method thereof | |
| CN102077945A (en) | Special dietary seafood for postabortal and postpartum women | |
| CN109393262A (en) | A kind of collagen Cranberry fruit drink and preparation method thereof | |
| CN102077938A (en) | Special marine dietary food for patients with liver deficiency | |
| CN111467481A (en) | Composition for improving and/or preventing osteoarthritis and application thereof | |
| CN104473084A (en) | Multi-vitamin nutrient chewable tablet prepared from blueberry peel and residues | |
| KR101513855B1 (en) | A composition for the treatment or prevention of osteoarthrits comprising an extract of crinum asiaticum | |
| CN102077944B (en) | Marine special dietary food special for prostate patient | |
| CN107616507A (en) | A kind of ocean polypeptide spy's dietary seafood for chornic arthritis edible for patients | |
| RU2483644C2 (en) | Method for production of dry product of brown algae and food product based thereon (versions) | |
| CN112675295A (en) | Blueberry powder compound solid preparation capable of preventing and improving osteoarthritis and preparation method and application thereof | |
| CN1718117A (en) | Instant drinking powder contg. black-fungus, oatmeal and spirulina, and its prepn. method | |
| CN109601680A (en) | A kind of maintenance joint and the Astaxanthin In Haematococcus Pluvialis pressed candy of connective tissue health and preparation method thereof | |
| CN114365850A (en) | Polypeptide composition with function of improving cartilage health and preparation method thereof | |
| CN107788526A (en) | A kind of nutriment for protecting Bones and joints | |
| CN112189839A (en) | Composition for assisting in reducing blood fat and application thereof | |
| CN112273490A (en) | Hawthorn and ginger tea potion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210420 |